XBiotech
XBIT
45 hedge funds and large institutions have $17M invested in XBiotech in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 3 closing their positions.
163% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 8
0.38% more ownership
Funds ownership: 10.62% → 11% (+0.38%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
4% less capital invested
Capital invested by funds: $17.6M → $17M (-$645K)
2% less funds holding
Funds holding: 46 → 45 (-1)
87% less call options, than puts
Call options by funds: $132K | Put options by funds: $1.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$213K |
| 2 |
Charles Schwab
San Francisco,
California
|
+$210K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$191K |
| 4 |
BlackRock
New York
|
+$141K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$160K |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
-$123K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$92.8K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$44.8K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$26.3K |
XBIT Hedge Fund Activity: Q3 2017 in Review
45 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q3 2017, worth a combined $17M — down 3.7% from $17.6M a quarter earlier.
Fund positioning in XBIT was balanced in Q3 2017: 3 funds opened new positions, 3 closed out, 21 added to existing stakes and 8 trimmed.
The largest buyer was Credit Suisse, adding an estimated $213K. The largest seller was Goldman Sachs, cutting an estimated $160K.
- 45 institutional investors held XBiotech (XBIT) as of Q3 2017, down from 46 in Q2 2017.
- Funds reported $17M of XBiotech stock for Q3 2017, down 3.7% quarter-over-quarter.
- 3 funds opened new XBiotech positions in Q3 2017 and 3 closed out, a net change of 0 holders.
- The largest XBiotech buyer in Q3 2017 was Credit Suisse, an estimated $213K added.
- The largest XBiotech seller in Q3 2017 was Goldman Sachs, an estimated $160K sold.
Based on aggregated 13F filings for Q3 2017.